Skip to content

Pharmacokinetics and pharmacodynamics of teicoplanin in the critically ill patients

Pharmacokinetics and pharmacodynamics of teicoplanin in the critically ill patients

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019344
Enrollment
Unknown
Registered
2018-11-06
Start date
2018-12-15
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection

Interventions

Group 1:Ordinary treatment with teicoplanin.
Group 2:Ordinary treatment with teicoplanin.

Sponsors

Guangdong General Hospital (Guandong Academy of Medical Sciences)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The patients who are treated with teicoplanin by intravenous infusion. 2. Male or female with age above 18 years. 3. Patitents who are diagnosed by the clinician with Gram-positive cocci include one of the following respiratory infections, bloodstream infection, catheter-related infection, infective endocarditis, neutropenia, fever, bone and joint infection, abdominal infection, skin and soft tissue.

Exclusion criteria

Exclusion criteria: 1. Teicoplanin is given not by intravenous infusion. 2. Teicoplanin is given for preventive use. 3. The patient is dead within 24 hours with the treatment of teicoplanin.

Design outcomes

Primary

MeasureTime frame
Plasma concentration of teicoplanin;

Countries

China

Contacts

Public ContactChunbo Chen

Guangdong General Hospital (Guandong Academy of Medical Sciences)

gghccm@163.com+86 13922745788

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026